Comparative safety and cardiovascular effectiveness of sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists in nursing homes
Main finding · DeathResult — go to the resultHazard ratio 1.18 95% CI 1.02–1.36Authors' conclusion
SGLT2is do not have superior, and may have inferior, effectiveness compared with GLP-1RAs for cardiovascular and mortality outcomes in NH residents. Residents initiating SGLT2is should be monitored closely for DKA.
Study context
- Population
- US nursing home residents aged ≥66 years with T2D initiating an SGLT2i or GLP-1RA, 2013–201831.08% SGLT2i, 68.92% GLP-1RA
- Participants
- 7,710 participants
- Exposure
- SGLT2i vs GLP-1 RA initiation
- Outcome
- Death
- Follow-up
- Year following treatment initiation
Methodological detailsper-protocol, stabilized inverse probability of treatment and censoring weighted, 127 covariates
- Per-protocol
- Stabilized inverse probability of treatment and censoring weighted
- 127 covariates
Main finding
As reported in the abstract
Hazard ratio
1.18
95% CI 1.02–1.36
SGLT2ivs GLP-1RA
HR 1.18 (95% CI 1.02–1.36)
Observational data: associations, not effects.
Further findings
MACE and hospitalization for HF
- Elevated with SGLT2i but imprecise and highly compatible with no difference
Safety
| Outcome | HR (95% CI) | |
|---|---|---|
| DKA · year following treatment initiationPer-protocol adjusted | 1.95 (1.27–2.99) | |
| 0.20.5125Hazard ratio (log scale) |
Urinary tract or genital infection, acute kidney injury, fall-related injuries, hypoglycaemia
- Urinary tract or genital infection and acute kidney injury elevated, fall-related injuries and hypoglycaemia reduced with SGLT2i; all estimates imprecise and highly compatible with no difference
Original publication
Comparative safety and cardiovascular effectiveness of sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists in nursing homes. Diabetes Obes Metab. Published 23 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →